Golden Biotech Signs Agreement with Fortrea Inc. to Request an End-of-Phase 2 (EOP2) Meeting with the US FDA

ASCO GI 2024: Golden Biotech's Antroquinonol Shows Significantly Prolonged Survival in Untreated Metastatic Pancreatic Cancer Patients (Yahoo Finance)

ASCO® GI 2024: GoldenBiotech’s Phase 2 Metastatic Pancreatic Cancer Study Selected for Poster Presentation and Discussion (Abstract # 648. Poster Bd. # K17)

Congratulations to GoldenBiotech’s Independent Director Professor Wen-Wei Hsu, Honorary President of Chang Gung Memorial Hospital in Chiayi, Awarded as “WORLD’S TOP 2% SCIENTISTS”

Golden Biotech Announces Positive Results with Longer Survival Compared with Standard Treatments from Interim Analysis of Phase 2 Trial for Antroquinonol as 1st Line Treatment for Stage 4 Metastatic Pancreatic Cancer

Golden Biotech Signs the Definitive Licensing Agreement with BNC Korea for the Development of Antroquinonol in COVID-19

GoldenBiotech Received FDA AoR of its Pre-EUA Meeting Request for COVID-19 Trial Drug Antroquinonol

GoldenBiotech Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Patients

GoldenBiotech’s Oral COVID-19 New Drug Trial of Antroquinonol Got Green Light from the FDA to Extend Recruiting Severe COVID-19 Patients

GoldenBiotech signs MOU with Sanova Pharma GesmbH for cooperation and development of Antroquinonol in 23 European Countries

GoldenBiotech HOCENA Granted Compassionate Use by the TFDA for Treatment of Covid-19 Patients

Covid-19 Trial_GoldenBiotech New Drug Antroquinonol Passed 2nd DMC Review in the USA